Dear Editor,

Mucopolysaccharidosis IVA (Morquio syndrome) is a cause of morbidity in early or late childhood, depending on disease severity. It is an autosomal recessive disorder characterized by short stature and multiple skeletal abnormalities. A deficiency of N-acetylgalactosamine-6-sulfate sulfatase (GALNS) activity, due to mutations in the GALNS gene, leads to the accumulation of keratan sulfate, which destroys cartilage tissue before epiphyseal closure (1). Moreover, respiratory compromise, as well as cardiac, ocular, dental, hearing, and neurologic impairments, are consequences of disease progression (2, 3).

Early and accurate diagnosis, based on the detection of low enzyme activity or through molecular genetic testing, may facilitate early intervention and improve the quality of life for affected children (4–6).

To date, the number of identified mutations in this disease continues to increase. We aim to introduce a novel missense point mutation in the GALNS gene that is associated with a severe form of MPS IVA. This mutation was detected in a three-year-old girl, born of consanguineous parents, who presented with genu valgus, pectus carinatum, cupping of the wrists, ulnar deviation of the radius and ulna, and kyphoscoliosis (Figure 1). The Berry spot test of the urine was positive for

Mucopolysaccharides (Figure 2). Cell blood count, eythrocyte sedimentation rate, fasting blood sugar, creatine phosphokinase, calcium, phosphorous, alkaline phosphatase, amylase, and 25-OH-vitamin D levels were all within the normal range.

Fig. 2. Positive urine Berry spot test in our case.

Whole exome sequencing, performed using the Illumina Novaseq 6000 system (151 bp paired-ends read, depth of coverage: 100x) and compared with the published human genome build (UCSC hg19 reference sequence), revealed a c.965C>T (p.Ala322Val) missense variant in both alleles of the GALNS gene. This variant is classified as a likely pathogenic variant according to the American College of Medical Genetics (ACMG) guidelines, which is consistent with a molecular diagnosis of Mucopolysaccharidosis IVA.

In conclusion, this novel mutation is associated with severe form of MPS IVA.  Early detection of this genetic alteration in a suspected patient, may help in in early treatment with enzyme, prediction of disease severity and provide a better quality of life by early intervention.

Funding

This research received no specific grant from any funding agency in the public, commercial, or not-for-profit sector.

Authors' Contributions

Safavi M: Conceptualization, Formal analysis, Supervision, Writing - review & editing. Ghoddoosi M: Conceptualization, Formal analysis, Writing - review & editing. Setoodeh A: Resources, Writing - review & editing.

Conflict of Interest

The authors declared no conflict of interest.